Increased Levels of Soluble CD30 in Plasma of Patients with *Plasmodium falciparum* Malaria

Kåre Kemp,1* Jørgen A. L. Kurtzhals,1,2,3 Bartholomew D. Akanmori,2 Victoria Adabayeri,3 Bamenla Q. Goka,3 Charlotte Behr,4 and Lars Hviid1

Center for Medical Parasitology, Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), and Institute for Medical Microbiology and Immunology, University of Copenhagen, Copenhagen, Denmark; Immunology Unit, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon; and Department of Child Health, Korle-Bu Teaching Hospital, University of Ghana Medical School, Accra, Ghana; and Unité d’Immunologie Moléculaire des Parasites, CNRS URA 1960, Institut Pasteur, Paris, France

Received 19 June 2001/Returned for modification 22 October 2001/Accepted 22 January 2002

Levels of soluble CD30 (sCD30) in serum were elevated in patients with *Plasmodium falciparum* malaria but showed decline following treatment. The levels of sCD30 in serum were correlated significantly with the expression of gamma interferon by peripheral T cells. These data suggest that CD30 cells are upregulated during a malaria attack and that they may play a regulating role at the site of inflammation.

Malaria is associated with the activation and redistribution of T cells (9), but the role of these cells during infection still remains unclear.

CD30 is a member of the tumor necrosis factor-nerve growth factor superfamily (2, 16) and is expressed mostly on a subset of activated CD4+ CD45RO+ cells (4) but also on activated γδ T cells (1). In vitro CD30+ T-cell clones express T-helper 2 or 0 cytokines, although CD30 cannot be used as a marker for the identification of Th2 cells (7, 13).

Recently, CD30+ T cells have been suggested to have a counterregulatory activity as part of a homeostatic response that attempts to control inflammation in Th1-driven diseases (5), probably as a consequence of the production of anti-inflammatory cytokines.

To determine whether CD30 could be involved in the pathogenesis of malaria, we measured levels of soluble CD30 (sCD30) in plasma samples from Ghanaian children with malaria.

All the children (∼21) were admitted as inpatients to the Department of Child Health, Korle-Bu Teaching Hospital, Accra, Ghana, with a diagnosis of *Plasmodium falciparum* malaria. Only patients that could be categorized as having cerebral malaria, severe anemia, or uncomplicated malaria, according to a set of strict inclusion and exclusion criteria described elsewhere, were admitted (12), and all had elevated levels of plasma gamma interferon (IFN-γ) (data not shown). All patients were treated with standard regimens of chloroquine or artemisinin, and all recovered fully from their infections. In addition to the malaria patients, we also included a group of age-matched, healthy children from a nearby community (∼21).

This study was approved by the Ethical and Protocol Review Committee, University of Ghana Medical School, and by the Ghanaian Ministry of Health.

* Corresponding author. Mailing address: Department of Infectious Diseases M7641, Rigshospitalet, Tagensvej 20, 2200 Copenhagen N, Denmark. Phone: 45 35 45 73 75. Fax: 45 35 45 76 44. E-mail: kkcemp@rh.dk.

Peripheral blood samples were obtained on days 0 (admission), 2, 3, 7, 14, and 30 (for investigation of levels of sCD30 in plasma) or on day 0 (for investigation of expression of IFN-γ by T cells). From each of the healthy control donors, only a single blood sample was obtained.

Plasma was separated from the heparinized blood and stored at −20°C until analysis. sCD30 was measured by enzyme-linked immunosorbent assay (CD30 [K-1 antigen]; DAKO, Glostrup, Denmark).

Peripheral blood mononuclear cells (PBMC) were isolated by gradient centrifugation and cryopreserved at −196°C until time of assay, as previously described (8).

For intracellular staining of IFN-γ, PBMC were resuspended in RPMI 1640, supplemented with 15% heat-inactivated pooled human serum−20 IU of penicillin/ml−20 μg of streptomycin (Gibco, Paisley, United Kingdom)/ml, and seeded into 24-well multidish plates (Nunc, Roskilde, Denmark). Each well contained 10⁶ PBMC in 1 ml of medium. The cells were cultured at 37°C in a humidified atmosphere with 5% CO₂ and incubated with a solution containing 1.5 μM monensin (Sigma, St. Louis, Mo.), 1 μM ionomycin, and 50 ng of phorbol myristate acetate/ml for 4 h. Intracellular cytokine staining was based on the method of another study (10). In brief, cells were harvested, washed in phosphate-buffered saline (PBS), resuspended in PBS containing 0.5% bovine serum albumin and 0.01% NaN₃ (staining buffer), and labeled with antibody directed against CD3 (UCHT1; DAKO). The cells were then washed twice in PBS-bovine serum albumin-Na₂₃, fixed with 2% formaldehyde (Sigma) in staining buffer, washed twice in staining buffer, and twice in a freshly made saponin buffer (staining buffer containing 0.1% [wt/vol] saponin [Sigma]), and finally incubated with anti-IFN-γ (Pharmingen, San Diego, Calif.). Following cytokine labeling, the cells were washed twice in saponin buffer and twice in staining buffer, resuspended in the staining buffer, and analyzed on an EPICS XL-multi carousel loader flow cytometer (Coulter, Miami, Fla.). Analysis of the data was done with Winlist software (Verity, Topsham, Maine).

Different groups were compared by analysis of variance by...
levels of sCD30 are not associated with a rise in the CD30+/H11001 others such as human immunodeficiency virus (15), increased levels of sCD30 in plasma concomitant with the absence of CD30+ T cells from blood in circulation (data not shown). This suggests that CD30+ T cells probably play a role at the site of inflammation and are redistributed away from the periphery during the infection, as previously suggested with malaria-antigen-reactive T cells (3).

Recently, a study of rheumatoid arthritis (5) has suggested a regulatory role for CD30+ T cells where CD30+ T cells are distributed to sites of inflammation to subdue damage.

Increased IFN-γ production in cells by peripheral T cells may reflect increased inflammation, and in this study, increased levels of sCD30 were correlated to high frequencies of IFN-γ-producing T cells (Fig 2). This correlation was not found between sCD30 and peripheral cells expressing interleukin-4 (data not shown).

The data in this study suggest that a subset of CD30+ cells is upregulated during malaria and that these cells may act as counterregulating cells in response to increased inflammation.

This work was supported by grants from the Danish International Development Agency (RUF and the ENRECA programs), the Danish Biotechnology Program, and the Novo Nordisk Foundation.

G. Grauer is thanked for excellent technical support.

REFERENCES
6. Gerli, R., D. Monti, O. Bistoni, A. M. Mazzone, G. Peri, A. Cossarizza, M. Di Gioacchino, M. E. Cesarotti, A. Doni, A. Mantovani, C. Franceschi, and R. Biocca. 2000. The origin of the detected CD30 was not clear since the increased levels of sCD30 were concomitant with the absence of CD30+ T cells from blood in circulation (data not shown). This suggests that CD30+ T cells probably play a role at the site of inflammation and are redistributed away from the periphery during the infection, as previously suggested with malaria-antigen-reactive T cells (3).

Recently, a study of rheumatoid arthritis (5) has suggested a regulatory role for CD30+ T cells where CD30+ T cells are distributed to sites of inflammation to subdue damage.

Increased IFN-γ production in cells by peripheral T cells may reflect increased inflammation, and in this study, increased levels of sCD30 were correlated to high frequencies of IFN-γ-producing T cells (Fig 2). This correlation was not found between sCD30 and peripheral cells expressing interleukin-4 (data not shown).

The data in this study suggest that a subset of CD30+ cells is upregulated during malaria and that these cells may act as counterregulating cells in response to increased inflammation.

This work was supported by grants from the Danish International Development Agency (RUF and the ENRECA programs), the Danish Biotechnology Program, and the Novo Nordisk Foundation.

G. Grauer is thanked for excellent technical support.

REFERENCES
722 NOTES CLIN. DIAGN. LAB. IMMUNOL.


